Roche Gains FDA Approval For Cytomegalovirus Test

Law360, Washington (July 5, 2012, 5:02 PM EDT) -- The U.S. Food and Drug Administration on Thursday approved a Roche Holding AG DNA test to track levels of a common virus that can cause serious side effects in solid organ transplant patients, saying the test will enhance transplant patient care.

Roche's COBAS AmpliPrep/COBAS TaqMan CMV Test tracks cytomegalovirus loads in patients' blood to determine the efficacy of anti-CMV treatments. The virus can cause pneumonia, colitis or other serious diseases in heart, lung, kidney, pancreas and small intestine transplant patients as well as other immunocompromised individuals,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.